‘Folfirinox’ chemotherapy combined with contact x-ray brachytherapy 50kVp and ‘CAP50’ chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study

The standard treatment of T2–T3 rectal adenocarcinoma is radical proctectomy by total mesorectal excision often combined with some neoadjuvant treatment. To reduce morbidity of this surgery, organ preservation strategy using various combination of radiotherapy, chemotherapy and local excision is gai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer radiothérapie 2024-08, Vol.28 (4), p.323-332
Hauptverfasser: Mitrea, D., Barbet, N., Pacé-Loscos, T., Scouarnec, C., Ben-Dhia, S., Baron, D., Mineur, L., Évesque, L., Durand-Labrunie, J., Gérard, J.-P., Baudin, G., Doyen, J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The standard treatment of T2–T3 rectal adenocarcinoma is radical proctectomy by total mesorectal excision often combined with some neoadjuvant treatment. To reduce morbidity of this surgery, organ preservation strategy using various combination of radiotherapy, chemotherapy and local excision is gaining interest. Some randomized trials have proven the feasibility of such approaches. The OPERA trial demonstrated, for T2 T3
ISSN:1278-3218
1769-6658
1769-6658
DOI:10.1016/j.canrad.2024.02.003